Catalyst Pharmaceuticals, Inc.
ISIN US14888U1016
|WKN A0LCUL
Overview
Description
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 2,330.03 m |
| EPS, EUR | 1.21 |
| P/B ratio | 3.56 |
| P/E ratio | 16.35 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 454.60 m |
| Net income, EUR | 151.51 m |
| Profit margin | 33.33% |
What ETF is Catalyst Pharmaceuticals, Inc. in?
There are 22 ETFs which contain Catalyst Pharmaceuticals, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Catalyst Pharmaceuticals, Inc. is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
